Lessons from the neoadjuvant setting on how best to choose adjuvant therapies

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Von Minckwitz, Gunter ^a   Loibl, Sibylle ^a   Maisch, Andrea ^a   Untch, Michael ^b  

^a GERMAN BREAST GROUP   (Germany)

^b Helios Kliniken Wismarsche S   (Germany)

Author keywords

Breast cancer; Chemotherapy; Neoadjuvant; Pathological complete response; Predictive factors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PERTUZUMAB; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 80054858362     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70312-5     Document Type: Article

References (19)

1. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008 Feb 10, 26(5):778-785. Erratum: 26(16):2793.
2. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008 Jan l, 26(l):44-53.
3. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010 Jan 30, 375(9712):377-384.
4. Untch M, Fasching AP, Konecny EG, Hasmiiller S, Lebeau A, Kreienberg R, et al. Pathological complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in HER2-overexpressing breast cancer - Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011, in press.
5. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010, 124:133-140.
6. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin. Oncol 2008 Mar 10, 26(8):1275-1281.
7. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008, 100(8):542-551.
8. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, for the German Breast Group and Arbeitsgemeinschaft Gynakologische Onkologie - Brust investigators, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2010, 22(2):301-306.
9. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Capecitabine in addition to anthracycline/taxane-based neoadjuvant treatment in patients with primary breast cancer: the phase III GeparQuattro study. J Clin Oncol 2010, 28(12):2015-2023.
10. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, for the German Breast Group and AGO Breast Group, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from GeparQuatro study. J Clin Oncol 2010, 28(12):2024-2031.
11. von Minckwitz G, Zahm MD, Eidtmann H, Tesch H, du Bois A, Schwedler K, et al. Zoledronic acid (ZOL) as add on therapy in patients with tumor residuals after neoadjuvant chemotherapy for primary breast cancer - first interim safety analysis of the NATAN study (GBG 36). EurJ Cancer 2010, 8(3):65.
12. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691.
13. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristicsJNar/. Cancer Inst 2008 Oct 1, 100(19):1380-1388.
14. von Minckwitz G, Untch M, Nuesch E, Loibl S, Kaufmann M, Kummel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011, 125(l):145-156.
15. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res 2010, 70(24 Suppl). abstract S3-2.
16. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, on behalf of the NeoALTTO Study Team, et al. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res 2010, 70(24 Suppl). abstract S3-3.
17. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, for the GBG/AGO study group, et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GeparQuinto study (GBG 44). Cancer Res 2010, 70(24 Suppl):81s. (abstract S3-1).
18. von Minckwitz G, Eidtmann H, Rezai M, Fasching R, Tesch H, Costa SD, for the GBG/AGO study groups, et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GeparQuinto Study (GBG 44). Cancer Res 2010, 70(24 Suppl):86s. (abstract S4-6).
19. von Minckwitz G, Muller MB, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, for GBG investigators, et al. Cytoplasmic PARP expression is predictive and prognostic in breast cancer patients treated by neoadjuvant chemotherapy. JClin Oncol 2011, in press.